Source:http://linkedlifedata.com/resource/pubmed/id/20359886
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2010-5-3
|
| pubmed:abstractText |
The 70-gene signature (MammaPrint) is a prognostic test used to guide adjuvant treatment decisions in patients with node-negative breast cancer. In order to decide upon its use, a systematic comparative analysis of the effects of the 70-gene signature, the Sankt Gallen guidelines and the Adjuvant Online Software for these patients on survival, quality of life and costs is warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1879-0852
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1382-91
|
| pubmed:meshHeading |
pubmed-meshheading:20359886-Breast Neoplasms,
pubmed-meshheading:20359886-Chemotherapy, Adjuvant,
pubmed-meshheading:20359886-Cost-Benefit Analysis,
pubmed-meshheading:20359886-Disease Progression,
pubmed-meshheading:20359886-Female,
pubmed-meshheading:20359886-Humans,
pubmed-meshheading:20359886-Markov Chains,
pubmed-meshheading:20359886-Neoplasm Staging,
pubmed-meshheading:20359886-Practice Guidelines as Topic,
pubmed-meshheading:20359886-Prognosis,
pubmed-meshheading:20359886-Sensitivity and Specificity
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
|
| pubmed:affiliation |
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), Department of Psychosocial Research and Epidemiology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|